Atara Biotherapeutics Past Earnings Performance
Past criteria checks 0/6
Atara Biotherapeutics's earnings have been declining at an average annual rate of -1.7%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 63.1% per year.
Key information
-1.7%
Earnings growth rate
18.5%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 63.1% |
Return on equity | n/a |
Net Margin | -6,390.3% |
Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway
Feb 06Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely
Oct 17Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive
May 18Need To Know: Analysts Are Much More Bullish On Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
Feb 13Analysts Have Just Cut Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Revenue Estimates By 16%
Nov 22EMA panel backs approval of Atara's Ebvallo for transplant complication
Oct 14Atara Bio to get additional $30M milestone payment under collaboration with Pierre Fabre
Sep 28Atara: 2 Possible Regulatory Approvals For Tab-Cel, Plus CAR T Pipeline
Aug 17Atara adds 16% ahead of Phase 2 data for multiple sclerosis candidate
Jul 12Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Intrinsic Value Is Potentially 42% Above Its Share Price
Jul 03Time To Worry? Analysts Just Downgraded Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Outlook
May 11Analysts Are Updating Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Estimates After Its Annual Results
Mar 02Atara Biotherapeutics: Early Stage Promises, Late Stage Delays
Feb 27Revenue & Expenses BreakdownBeta
How Atara Biotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 23 | 5 | -290 | 49 | 235 |
30 Jun 23 | 7 | -305 | 56 | 270 |
31 Mar 23 | 57 | -215 | 61 | 270 |
31 Dec 22 | 64 | -228 | 68 | 270 |
30 Sep 22 | 71 | -247 | 80 | 282 |
30 Jun 22 | 72 | -248 | 81 | 282 |
31 Mar 22 | 24 | -350 | 82 | 282 |
31 Dec 21 | 20 | -340 | 79 | 282 |
30 Sep 21 | 13 | -328 | 73 | 245 |
30 Jun 21 | 7 | -318 | 68 | 245 |
31 Mar 21 | 4 | -311 | 65 | 245 |
31 Dec 20 | 0 | -307 | 64 | 245 |
30 Sep 20 | 0 | -304 | 66 | 62 |
30 Jun 20 | 0 | -301 | 71 | 115 |
31 Mar 20 | 0 | -298 | 77 | 167 |
31 Dec 19 | 0 | -291 | 80 | 216 |
30 Sep 19 | 0 | -292 | 81 | 204 |
30 Jun 19 | 0 | -279 | 79 | 194 |
31 Mar 19 | 0 | -256 | 75 | 175 |
31 Dec 18 | 0 | -231 | 70 | 167 |
30 Sep 18 | 0 | -186 | 61 | 130 |
30 Jun 18 | 0 | -159 | 55 | 107 |
31 Mar 18 | 0 | -135 | 46 | 92 |
31 Dec 17 | 0 | -119 | 40 | 81 |
30 Sep 17 | 0 | -102 | 35 | 70 |
30 Jun 17 | 0 | -97 | 31 | 68 |
31 Mar 17 | 0 | -88 | 28 | 63 |
31 Dec 16 | 0 | -79 | 25 | 57 |
30 Sep 16 | 0 | -82 | 25 | 59 |
30 Jun 16 | 0 | -69 | 22 | 49 |
31 Mar 16 | 0 | -65 | 19 | 47 |
31 Dec 15 | 0 | -57 | 17 | 42 |
30 Sep 15 | 0 | -46 | 17 | 30 |
30 Jun 15 | 0 | -41 | 14 | 27 |
31 Mar 15 | 0 | -30 | 12 | 18 |
31 Dec 14 | 0 | -28 | 13 | 15 |
30 Sep 14 | 0 | -21 | 8 | 13 |
30 Jun 14 | 0 | -18 | 7 | 10 |
31 Mar 14 | 0 | -15 | 7 | 7 |
Quality Earnings: ATRA is currently unprofitable.
Growing Profit Margin: ATRA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ATRA is unprofitable, and losses have increased over the past 5 years at a rate of 1.7% per year.
Accelerating Growth: Unable to compare ATRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: ATRA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.